🇪🇺 Fremanezumab-Vfrm in European Union

EMA authorised Fremanezumab-Vfrm on 28 March 2019

Marketing authorisation

EMA — authorised 28 March 2019

  • Application: EMEA/H/C/004833
  • Marketing authorisation holder: Teva GmbH
  • Local brand name: Ajovy
  • Indication: Ajovy is indicated for prophylaxis of migraine in adults who have at least 4 migraine days per month.
  • Status: approved

Read official source →

Fremanezumab-Vfrm in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is Fremanezumab-Vfrm approved in European Union?

Yes. EMA authorised it on 28 March 2019.

Who is the marketing authorisation holder for Fremanezumab-Vfrm in European Union?

Teva GmbH holds the EU marketing authorisation.